BioInvent International AB brings forward publication of Year-end report 2020

Lund, Sweden – February 23, 2021 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announces that the company changes the date for publication of the year-end report 2020, and the interim report for the fourth quarter 2020, to Tuesday February 23, 2021. Earlier communicated publication date was February 25, 2021.

About BioInvent
BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations                Mary-Ann Chang, LifeSci Advisors
+46 (0)46 286 85 50                                   +44 7483 284 853
cecilia.hofvander@bioinvent.com              mchang@lifesciadvisors.com

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.comThis information was submitted for publication, through the agency of the contact person set our above, at 6:45 a.m. CET on February 23, 2021.